Skip to content

Search

Prevalence and determinants of influenza vaccine coverage at tertiary pediatric hospitals

This study aimed to examine the uptake of influenza vaccination amongst a cohort of Australian children and factors associated with vaccine acceptance.

Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocol

We aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.

Systemic antibiotics for chronic suppurative otitis media

To assess the effects of systemic antibiotics for people with chronic suppurative otitis media.

Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia

Our population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection

Parental pre-pregnancy BMI is a dominant early-life risk factor influencing BMI of offspring in adulthood

Parental pre-pregnancy body mass index and rapid early-life weight gain predispose offspring to obesity in adulthood

Informing rubella vaccination strategies in East Java, Indonesia through transmission modelling

A single dose of rubella vaccine will take longer to reduce the burden of rubella and will be less robust to lower vaccine coverage

Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study

Community perception of vaccine safety influences vaccine uptake. Our objective was to assess current vaccine safety monitoring by examining factors that may influence the availability of post-vaccination survey data, and thereby the specificity and sensitivity of existing signal detection methods.

Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia

Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023. 

Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies

Improved understanding of Salmonella Typhi infection can help accelerate the development of improved vaccines and diagnostic tests necessary for disease control